Skip to content

Based on the real world prospective study, two-way analysis of the dominant population and corresponding phenotypic characteristics of patients with colorectal cancer treated by Fuzheng anti-tumor therapy combined with adjuvant chemotherapy

Based on the real world prospective study, two-way analysis of the dominant population and corresponding phenotypic characteristics of patients with colorectal cancer treated by Fuzheng anti-tumor therapy combined with adjuvant chemotherapy

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003460
Enrollment
Unknown
Registered
2020-07-05
Start date
2020-07-06
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Interventions

Sponsors

Department of Gastrointestinal surgery,Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) The age of the patients was 18-75 years old; (2) Radical resection of colorectal cancer (negative margin) was performed; (3) Patients with stage II high risk and stage III colorectal cancer confirmed by histology; (4) No liver, peritoneal or distant metastasis was found; (5) Patients with colorectal cancer who received standard chemotherapy or radiotherapy after operation and had no recurrence or metastasis at the end of radiotherapy and chemotherapy; (6) ECoG (Eastern Cooperative Oncology Group) score was 0-1; KPS score was 70 or above; (7) Liver function: SGOT and SGPT were less than 1.5 times of normal value, bilirubin was less than 1.5 mg / dl; (8) Renal function: creatinine < 1.8mg/dl.

Exclusion criteria

Exclusion criteria: (1) Allergic to the drug of this scheme; (2) Pregnant or lactating women with fertility requirements during the study period; (3) Severe hypertension, coronary heart disease, diabetes and so on, which are under control for half a year due to cardiovascular accident and poor drug control, are accompanied with other uncontrollable benign diseases such as lung, kidney, liver, infection, etc; (4) Participate in other studies before and during treatment; (5) There was a history of other malignant tumors or multi-source tumors within one year; (6) Chronic hepatitis B or C (high copy viral DNA) or activity in HIV infection history or active phase; (7) Patients with tuberculosis or seizures who need to be treated (e.g. steroids or antiepileptic therapy).

Design outcomes

Primary

MeasureTime frame
3 yeah Disease-free Survival;

Secondary

MeasureTime frame
OS;Quality of life;Median survival time;

Countries

China

Contacts

Public ContactWei Wang

Guangdong Provincial Hospital of Chinese Medicine

ww1640@yeah.net+86 13922255515

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026